1 DNA Way
South San Francisco
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1426 articles with Genentech, Inc.
– Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation – – Xolair is now FDA-approved across three diseases and in two formulations, continuing to build on the medicine’s 17 years of patient experience since its initial approval for allergic asthma –
Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with advanced or metastatic RET
Amidst a global pandemic, the life sciences industry is booming! BioSpace rounds up facility expansions and employment opportunities across the states and beyond.
Although biopharma executives leave for many reasons and at any time, there is a tendency to make shifts toward the end of the year. Today there were two high-profile announcements to start off the month of December.
Genentech’s influenza treatment Xofluza® (baloxavir marboxil) has been granted approval by the U.S. Food and Drug Administration for use in people 12 years and older, making it the first single-dose post-exposure prophylaxis strategy approved by the agency.
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis)
OneOncology Partners with Genentech to Bring Personalized Cancer Research to Patients at Community Oncology Sites
Collaboration Will Advance Comprehensive Genomic Profiling, Clinical Trials and Real-World Data Studies for Cancer Patients
Genentech to Present New Data Across 16 Blood Disorders at the American Society of Hematology 2020 Annual Meeting
– New data for Genentech’s CD20xCD3 bispecific antibodies will be featured, as well as first clinical data on cevostamab, a first-of-its-kind FcRH5xCD3 bispecific antibody, in multiple myeloma – – Longer-term data for Genentech’s approved therapies in hemophilia A, chronic lymphocytic leukemia and diffuse large B-cell lymphoma reinforce the favorable efficacy and safety profile of each medicine –
Lodo Therapeutics Achieves Second Preclinical Milestone In Its Strategic Collaboration With Genentech
Lodo's Informatics-Enabled Drug Discovery Platform Accesses the Vast Collections of Undiscovered Drug-Like Molecules Encoded in Microbial DNA
GO2 Foundation for Lung Cancer "Simply the Best" XV Virtual Gala Honors Those Working on the Front Lines to Fight Lung Cancer
GO2 Foundation for Lung Cancer announced it will celebrate Genentech with the "Simply the Best Award" at its XV Virtual Annual Simply the Best Gala on November 14, 2020 at 6:30 pm PT.
Genesis Therapeutics, a privately-held company inventing and deploying state-of-the-art artificial intelligence techniques to augment drug discovery and development, announced that it has entered into a multi-target collaboration agreement with Genentech, a member of the Roche Group.
In this multi-target partnership, Genentech will leverage Genesis’ Dynamic PotentialNet AI platform and other novel neural network algorithms.
Collaboration to advance a first-in-class α9/α10 nAchR antagonist for the treatment of chronic pain into Phase 1 clinical trials
Forbion Portfolio Company, Enterprise Therapeutics’ First-in-Class TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired by Roche
Forbion, a leading European life sciences venture capital firm, announces that its portfolio company, Enterprise Therapeutics Ltd ’s novel TMEM16A potentiator portfolio has been fully acquired by Roche and will be developed by Genentech, a member of the Roche Group.
Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by Roche
Enterprise’s novel TMEM16A potentiator portfolio includes ETD002, a first in class compound which is currently in Phase 1
This morning, the Swiss pharma giant acquired a portfolio of experimental cystic fibrosis therapies, including a candidate that has the potential to treat all patients with this disease.
Imbio, a leading provider of artificial intelligence solutions for medical imaging analysis, has partnered with Genentech, a member of the Roche Group, to develop quantitative imaging diagnostics for lung diseases.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
"We are very excited to have entered into this transformative agreement that marks the start of a new era for Vaccibody,” Michael Engsig, CEO of Vaccibody, said in a statement.
Genentech Presents New 2-Year Data for Evrysdi (risdiplam) in Infants With Type 1 Spinal Muscular Atrophy (SMA)
Exploratory efficacy data showed 88% of infants treated with Evrysdi were alive and did not require permanent ventilation at two years